Description: Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's Disease and Amyotrophic Lateral Sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type; and ALPHA-0602, a gene therapy program for the treatment of ALS. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Home Page: www.alphacognition.com
750 West Pender Street
Vancouver,
BC
V6C 2T8
Canada
Phone:
604-564-9244
Officers
| Name | Title |
|---|---|
| Mr. Michael E. McFadden B.B.A. | CEO & Director |
| Mr. Kenneth Anthony Cawkell B.A., LL.B. | Founder, Consultant, Corporate Secretary & Director |
| Ms. Lauren D'Angelo M.B.A. | Chief Operating Officer |
| Mr. Donald A. Kalkofen B.A. | Consultant |
| Dr. Denis G. Kay Ph.D. | Chief Scientific Officer |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 16.0514 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 445.518 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |